Purpose. This study evaluated the efficacy of 50% autologous serum eye drops in ocular surface diseases not improved by conventional therapy. Methods. We analyzed two groups: (1) acute eye pathologies (e. g., chemical burns) and (2) chronic eye pathologies (e. g., recurrent corneal erosion, neurotropic keratitis, and keratoconjunctivitis sicca). The patients were treated for surface instability after conventional therapy. The patients received therapy 5 times a day until stabilization of the framework; they then reduced therapy to 3 times a day for at least 3 months. We analyzed the best corrected visual acuity, epithelial defects, inflammation, corneal opacity, and corneal neovascularization. We also analyzed symptoms such as tearing, burning, sense of foreign body or sand, photophobia, blurred vision, and difficulty opening the eyelids. Results. We enrolled 15 eyes in group 1 and 11 eyes in group 2. The average therapy period was 16 +/- 5.86 weeks in group 1 and 30.54 +/- 20.33 weeks in group 2. The epithelial defects all resolved. Signs and symptoms improved in both groups. In group 2, the defect recurred after the suspension of therapy in 2 (18%) patients; in group 1, no defects recurred. Conclusions. Autologous serum eye drops effectively stabilize and improve signs and symptoms in eyes previously treated with conventional therapy.

Evaluation of the efficacy of 50% autologous serum eye drops in different ocular surface pathologies

SEMERARO, Francesco;FORBICE, Eliana Maria;DI SALVATORE, Attilio;
2014-01-01

Abstract

Purpose. This study evaluated the efficacy of 50% autologous serum eye drops in ocular surface diseases not improved by conventional therapy. Methods. We analyzed two groups: (1) acute eye pathologies (e. g., chemical burns) and (2) chronic eye pathologies (e. g., recurrent corneal erosion, neurotropic keratitis, and keratoconjunctivitis sicca). The patients were treated for surface instability after conventional therapy. The patients received therapy 5 times a day until stabilization of the framework; they then reduced therapy to 3 times a day for at least 3 months. We analyzed the best corrected visual acuity, epithelial defects, inflammation, corneal opacity, and corneal neovascularization. We also analyzed symptoms such as tearing, burning, sense of foreign body or sand, photophobia, blurred vision, and difficulty opening the eyelids. Results. We enrolled 15 eyes in group 1 and 11 eyes in group 2. The average therapy period was 16 +/- 5.86 weeks in group 1 and 30.54 +/- 20.33 weeks in group 2. The epithelial defects all resolved. Signs and symptoms improved in both groups. In group 2, the defect recurred after the suspension of therapy in 2 (18%) patients; in group 1, no defects recurred. Conclusions. Autologous serum eye drops effectively stabilize and improve signs and symptoms in eyes previously treated with conventional therapy.
File in questo prodotto:
File Dimensione Formato  
BMRI2014- Siero Autologo 50%.pdf

gestori archivio

Descrizione: Bio Res 2014 autologous seum
Tipologia: Full Text
Licenza: DRM non definito
Dimensione 1.24 MB
Formato Adobe PDF
1.24 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11379/463874
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 53
  • ???jsp.display-item.citation.isi??? 41
social impact